文献速递临床试验与 GCP

创伤后出血早期经验性大剂量冷沉淀治疗:CRYOSTAT-2随机临床试验

Early and Empirical High-Dose Cryoprecipitate for Hemorrhage After Traumatic Injury: The CRYOSTAT-2 Randomized Clinical Trial.
PubMed 文献 · JAMA · 2023-01-01

CRYOSTAT-2是一项国际多中心随机开放标签平行对照研究,纳入26个英美主要创伤中心2017年8月至2021年11月的1604例需启动大出血方案的创伤出血成人患者,随机接受标准大出血方案或加用早期经验性大剂量冷沉淀。意向治疗人群28天全因死亡率标准护理组26.1% vs 冷沉淀组25.3%(OR 0.96,95%CI 0.75-1.23;P=0.74),安全性结局及血栓事件发生率无差异(12.9% vs 12.7%)。

要点

  • 创伤大出血患者加用早期经验性大剂量冷沉淀未改善28天全因死亡率。
  • 28天死亡率标准护理组26.1% vs 冷沉淀组25.3%,OR 0.96(95%CI 0.75-1.23;P=0.74)。
  • 安全性结局及血栓事件发生率标准护理组12.9% vs 冷沉淀组12.7%,无差异。

核心结论

  • 在需启动大出血方案的创伤出血患者中,标准护理加用早期经验性大剂量冷沉淀未改善28天全因死亡率。

研究设计与样本

  • CRYOSTAT-2为干预性、随机、开放标签、平行组对照、国际多中心研究,纳入26个英美主要创伤中心2017年8月至2021年11月收治的创伤出血成人患者。

主要发现

  • 意向治疗人群28天全因死亡率标准护理组26.1% vs 冷沉淀组25.3%(OR 0.96,95%CI 0.75-1.23;P=0.74)。
  • 安全性结局及血栓事件发生率标准护理组12.9% vs 冷沉淀组12.7%,无差异。
  • 1604例合格患者中799例随机分入冷沉淀组、805例分入标准护理组;73例缺失主要结局数据(主要因撤回知情同意),1531例(95%)纳入主要分析人群。

局限性

  • 73例患者缺失主要结局数据,主要因撤回知情同意。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Critical bleeding is associated with a high mortality rate in patients with trauma. Hemorrhage is exacerbated by a complex derangement of coagulation, including an acute fibrinogen deficiency. Management is fibrinogen replacement with cryoprecipitate transfusions or fibrinogen concentrate, usually administered relatively late during hemorrhage. OBJECTIVE: To assess whether survival could be improved by administering an early and empirical high dose of cryoprecipitate to all patients with trauma and bleeding that required activation of a major hemorrhage protocol. DESIGN, SETTING, AND PARTICIPANTS: CRYOSTAT-2 was an interventional, randomized, open-label, parallel-group controlled, international, multicenter study. Patients were enrolled at 26 UK and US major trauma centers from August 2017 to November 2021. Eligible patients were injured adults requiring activation of the hospital's major hemorrhage protocol with evidence of active hemorrhage, systolic blood pressure less than 90 mm Hg at any time, and receiving at least 1 U of a blood component transfusion. INTERVENTION: Patients were randomly assigned (in a 1:1 ratio) to receive standard care, which was the local major hemorrhage protocol (reviewed for guideline adherence), or cryoprecipitate, in which 3 pools of cryoprecipitate (6-g fibrinogen equivalent) were to be administered in addition to standard care within 90 minutes of randomization and 3 hours of injury. MAIN OUTCOMES AND MEASURES: The primary outcome was all-cause mortality at 28 days in the intention-to-treat population. RESULTS: Among 1604 eligible patients, 799 were randomized to the cryoprecipitate group and 805 to the standard care group. Missing primary outcome data occurred in 73 patients (principally due to withdrawal of consent) and 1531 (95%) were included in the primary analysis population. The median (IQR) age of participants was 39 (26-55) years, 1251 (79%) were men, median (IQR) Injury Severity Score was 29 (18-43), 36% had penetrating injury, and 33% had systolic blood pressure less than 90 mm Hg at hospital arrival. All-cause 28-day mortality in the intention-to-treat population was 26.1% in the standard care group vs 25.3% in the cryoprecipitate group (odds ratio, 0.96 [95% CI, 0.75-1.23]; P = .74). There was no difference in safety outcomes or incidence of thrombotic events in the standard care vs cryoprecipitate group (12.9% vs 12.7%). CONCLUSIONS AND RELEVANCE: Among patients with trauma and bleeding who required activation of a major hemorrhage protocol, the addition of early and empirical high-dose cryoprecipitate to standard care did not improve all cause 28-day mortality. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04704869; ISRCTN Identifier: ISRCTN14998314.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Davenport R, Curry N, Fox EE, et al. Early and Empirical High-Dose Cryoprecipitate for Hemorrhage After Traumatic Injury: The CRYOSTAT-2 Randomized Clinical Trial. JAMA. 2023. PMID: 37824155. doi:10.1001/jama.2023.21019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。